Logo Logo

Elsbernd, Kira ORCID: 0000-0003-1616-0212; Emmert-Fees, Karl M. F.; Erbe, Amanda; Ottobrino, Veronica; Kroidl, Arne; Bärnighausen, Till; Geisler, Benjamin P.; Kohler, Stefan (2022): Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review. Infectious Diseases of Poverty, 11: 82. ISSN 2049-9957

[thumbnail of s40249-022-01006-7.pdf] Veröffentlichte Publikation
s40249-022-01006-7.pdf

Die Publikation ist unter der Lizenz Creative Commons Namensnennung (CC BY) verfügbar.

Herunterladen (1MB)

Abstract

Background
Continuing progress in the global pediatric human immunodeficiency virus (HIV) response depends on timely identification and care of infants with HIV. As countries scale-out improvements to HIV early infant diagnosis (EID), economic evaluations are needed to inform program design and implementation. This scoping review aimed to summarize the available evidence and discuss practical implications of cost and cost-effectiveness analyses of HIV EID.

Methods
We systematically searched bibliographic databases (Embase, MEDLINE and EconLit) and grey literature for economic analyses of HIV EID in low- and middle-income countries published between January 2008 and June 2021. We extracted data on unit costs, cost savings, and incremental cost-effectiveness ratios as well as outcomes related to health and the HIV EID care process and summarized results in narrative and tabular formats. We converted unit costs to 2021 USD for easier comparison of costs across studies.

Results
After title and abstract screening of 1278 records and full-text review of 99 records, we included 29 studies: 17 cost analyses and 12 model-based cost-effectiveness analyses. Unit costs were 21.46–51.80 USD for point-of-care EID tests and 16.21–42.73 USD for laboratory-based EID tests. All cost-effectiveness analyses stated at least one of the interventions evaluated to be cost-effective. Most studies reported costs of EID testing strategies; however, few studies assessed the same intervention or reported costs in the same way, making comparison of costs across studies challenging. Limited data availability of context-appropriate costs and outcomes of children with HIV as well as structural heterogeneity of cost-effectiveness modelling studies limits generalizability of economic analyses of HIV EID.

Conclusions
The available cost and cost-effectiveness evidence for EID of HIV, while not directly comparable across studies, covers a broad range of interventions and suggests most interventions designed to improve EID are cost-effective or cost-saving. Further studies capturing costs and benefits of EID services as they are delivered in real-world settings are needed.

Publikation bearbeiten
Publikation bearbeiten